Multiparameter imaging flow cytometry-based cytokinesis-block micronucleus assay: Reduction of culture time and blood volume for improved efficiency.

In the event of a large-scale incident involving radiological or nuclear exposures, there is a potential for large numbers of individuals to have received doses of radiation sufficient to cause adverse health effects. It is imperative to quickly identify these individuals in order to provide information to the medical community to assist in making decisions about their treatment. The cytokinesis-block micronucleus assay is a well-established method for performing biodosimetry.

Interlaboratory comparison of high-throughput protein biomarker assay quantifications for radiation exposure classification.

In the event of a widespread radiological incident, thousands of individuals will require rapid assessment of exposure using validated biodosimetry assays to inform clinical triage. In this scenario, multiple biodosimetry laboratories may be necessary for large-volume sample processing. To meet this need, we have developed a high-throughput assay for the rapid measurement of intracellular protein biomarkers in human peripheral blood samples using an Imaging Flow Cytometry (IFC) platform.

Application of the Cytokinesis-Block Micronucleus Assay for High-Dose Exposures Using Imaging Flow Cytometry.

The cytokinesis-block micronucleus assay is a well-established method to assess radiation-induced genetic damage in human cells. This assay has been adapted to imaging flow cytometry (IFC), allowing automated analysis of many cells, and eliminating the need to create microscope slides. Furthermore, to improve the efficiency of assay performance, a small-volume method previously developed was employed.

[Vitiligo in an pair of enzygotic twins].

Investigations of twins can contribute in the investigation of hereditary factors participating in the etiopathogenesis of vitiligo. A 28-year-old pair of male twins are presented, whose monovularity was conclusively proved by a comparison of morphological and serological features. Vitiligo developed as a concordant feature at the age of 13 and 22 years respectively.